LC
STOK icon

Lindbrook Capital’s Stoke Therapeutics STOK Stock Holding History

Lindbrook Capital’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30
Closed -$369 – 2902
2024
Q3 		$369 Buy
+30
New +$425 ﹤0.01% 2729
2023
Q3 		– Sell
-412
Closed -$4.38K – 2819
2023
Q2 		$4.38K Sell
412
-123
-23% -$1.31K ﹤0.01% 1872
2023
Q1 		$4.46K Sell
535
-23
-4% -$208 ﹤0.01% 1898
2022
Q4 		$5.15K Buy
558
+554
+13,850% +$5.76K ﹤0.01% 1809
2022
Q3 		$0 Buy
+4
New +$64 ﹤0.01% 2897
2022
Q2 		– Sell
-101
Closed -$1.53K – 2757
2022
Q1 		$2K Buy
+101
New +$2.02K ﹤0.01% 2090

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Lindbrook Capital's STOK Position: Q4 2024 in Review

Lindbrook Capital sold out of Stoke Therapeutics (STOK) in Q4 2024, closing a stake of 30 shares — an estimated $369 sold.

Lindbrook Capital first reported a position in STOK in Q1 2022 and held it in 6 quarters. The position peaked at $5.15K in Q4 2022. 130 funds tracked by Wall St. Rank hold STOK as of Q4 2024.

  • Lindbrook Capital reported no remaining Stoke Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lindbrook Capital sold 30 Stoke Therapeutics shares in Q4 2024, an estimated $369.
  • Lindbrook Capital first reported a position in Stoke Therapeutics in Q1 2022 and held it in 6 quarters.
  • Lindbrook Capital's Stoke Therapeutics position peaked at $5.15K in Q4 2022.
  • 130 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2024.

Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.